Abstract: The present invention includes a method for harvesting or separating one or more biological cells from an aqueous feed, a stream, a suspension, or any combinations thereof by providing the aqueous feed, the stream, or the suspension comprising the one or more biological cells in a tank or a vessel; providing one or more ion-exchange resins, wherein the ion-exchange resin is an anion-exchange resin; contacting the anion-exchange resin with the aqueous feed; binding the one or more biological cells to the anion-exchange resin; releasing or eluting the bound one or more biological cells by changing the pH; and collecting the released one or more biological cells to obtain a concentrated slurry or suspension of the one or more biological cells.

Abstract: The disclosure provides a needle-electrode anchor system having a needle and an optional electrode with one or more anchors. The system can provide an electrical cutting current to the needle-electrode to create an opening in a tissue portion. An anchor coupled to the needle-electrode can be pushed through the opening with a pusher and pulled into position to set the anchor on a distal surface of the opening. If the tissue portion is to be approximated to another tissue portion, the system can be relocated to another tissue portion and another opening created with the cutting current with another anchor pushed through the opening and secured on a distal surface. Lines coupled to the anchors can be pulled together, approximating the tissue portions. If the tissue portion is to be retracted, an anchor line can be grasped to retract the tissue portion from an adjacent tissue portion.

Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.

Abstract: The present invention is directed to adenoviruses for use in cancer therapy which comprise one or more heterologous nucleic acid sequences encoding a tumor antigen, whereby the adenovirus expresses the tumor antigen(s) on its surface.

Abstract: This disclosure relates to novel herbal compositions comprising extracts of rosemary and oregano, and methods of using the herbal compositions to modulate inflammatory potential. One or both of the extracts may be supercritical extracts. The disclosure further relates to methods of treating inflammation, rheumatoid arthritis, osteoarthritis, or combinations thereof, using the herbal compositions.

Abstract: The present invention provides reagents and methods for improved homologous recombination.

Abstract: Methods for treating a subject determined to have a cancer comprising a heterozygous inactivation of a housekeeping gene (or a homozygous deletion of a functionally redundant housekeeping gene) by treating the subject with an inhibitor of the gene. For example, a subject having a cancer with an ENO gene deletion can be treated with a glycolysis inhibitor, such as an enolase inhibitor. In some aspects, a subject having a cancer with an ARS gene deletion can be treated with an ARS inhibitor.

Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Abstract: A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.

Abstract: Methods for detecting colorectal cancer in a subject by detection of a galactose-containing 40 kDa molecule in a serum sample from the subject. Methods for quantifying the amount of a galactose-containing molecule in a serum sample are also provided.

Abstract: The invention provides novel oligonucleotides and methods of using the same for detection or measurement of specific nucleic acid molecules. The invention also features nucleic acid arrays comprising the oligonucleotides of the invention. An oligonucleotide of the invention comprises (1) a reporter-binding sequence capable of hybridizing to a fluorophore-labeled reporter sequence and (2) a hairpin-forming sequence capable of forming a stem-loop. Formation of the stem-loop modifies (e.g., quenching) the fluorescence signals of the reporter sequence when the reporter sequence is hybridized to the oligonucleotide. This can be achieved, for example, by bringing one or more guanine based in the oligonucleotide into close proximity to the fluorophore(s) of the reporter sequence by virtue of the formation of the stem-loop. Disruption of the stem-loop, such as by hybridization of a target sequence to at least part of the hairpin-forming sequence, produces a detectable change in the fluorescence signals.

Abstract: The present invention provides compositions and methods for treating a cancer associated with elevated expression and/or activity of receptor tyrosine kinases (e.g., Eph receptors), such as EphA5. In some embodiments, the present invention provides compositions and methods for identifying elevated expression or activity of receptor tyrosine kinases (e.g., Eph receptors), such as EphA5.

Abstract: The disclosure provides novel graphene-reinforced ceramic composites and methods for making such composite materials.

Abstract: The present invention pertains to a bone marrow-directing drug delivery material that includes at least one fine particle, wherein the fine particle includes an anionic moiety on a surface of the particle. Also disclosed are uses of the material set forth herein for the prevention, treatment, or diagnosis of a disease of bone, cartilage, bone marrow, or a joint. Also disclosed are methods of preventing, treating, or diagnosing a disease of bone, cartilage, bone marrow, or a joint in a subject, involving administering to the subject a pharmaceutically effective amount of the material of the present invention.

Abstract: Estimating focus error in an image involves a training phase and an application phase. In the training phase, an optical system is represented by a point-spread function. An image sensor array is represented by one or more wavelength sensitivity functions, one or more noise functions, and one or more spatial sampling functions. The point-spread function is applied to image patches for each of multiple defocus levels within a specified range to produce training data. Each of the images for each defocus level (i.e. focus error) is sampled using the wavelength sensitivity and spatial sampling functions. Noise is added using the noise functions. The responses from the sensor array to the training data are used to generate defocus filters for estimating focus error within the specified range. The defocus filters are then applied to the image patches of the training data and joint probability distributions of filter responses to each defocus level are characterized.

Abstract: Biomedical scaffolds are described that may be used, for example, for the treatment of bone diseases and bone reconstruction and restoration. The described scaffolds having ingress and habitiaion property for cells and growth factors with serum by capillary action via engineered micro-channles. Also, the scaffolds permit nutrient and ion flow such that bone regeneration in the area surrounding the scaffold is promoted. Kits that include such scaffolds and methods of preparing and using such scaffolds are also provided.

Abstract: The present invention pertains to therapeutic compositions that comprise: (1) a nanovector, (2) an active agent; and (3) a targeting agent, wherein the active agent and the targeting agent are non-covalently associated with the nanovector. The present invention also pertains to methods of treating various conditions in a subject by utilizing the above-described therapeutic compositions. Methods of making the therapeutic compositions are also a subject matter the present invention.

Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: PARylated proteins are enriched by treating cell lysates comprising PARylated proteins and DNA/RNA with an endonuclease that cleaves the DNA/RNA but not the PAR; and separating the PARylated proteins from the cleaved DNA/RNA. PARylation sites are labeled by eluting PARylated proteins from a PAR-affinity substrate with a nucleophilic amine exchange reactant, wherein the reactant labels PARylation sites of the proteins. Specific binding agents are identified by screening compounds for specific binding to a PARylated protein disclosed herein; and identifying one of the compounds as a specific binder of the protein. Antibodies which specifically bind PARylation sites are also disclosed.